{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:33:56Z","timestamp":1791182036855,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":4298,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.exphem.2010.05.004","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T09:47:34Z","timestamp":1274953654000},"page":"782-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["KIT polymorphisms and mutations determine responses of neoplastic mast\u00a0cells to bafetinib (INNO-406)"],"prefix":"10.1016","volume":"38","author":[{"given":"Barbara","family":"Peter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Hadzijusufovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline V.","family":"Gleixner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried F.","family":"Pickl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuddow","family":"Thaiwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilma","family":"Yuzbasiyan-Gurkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Willmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2010.05.004_bib1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: state of the art","volume":"122","author":"Valent","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2010.05.004_bib2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.exphem.2010.05.004_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000101711","article-title":"Mastocytosis: state of the art","volume":"74","author":"Horny","year":"2007","journal-title":"Pathobiology"},{"key":"10.1016\/j.exphem.2010.05.004_bib4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.004_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal. Conference Report of \u201cYear 2000 Working Conference on Mastocytosis.\u201d","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.05.004_bib6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.05.004_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.0960-135X.2004.01369.x","article-title":"On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts","volume":"34","author":"Valent","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.exphem.2010.05.004_bib8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.beha.2005.07.010","article-title":"Pathogenesis, clinical features, and treatment advances in mastocytosis","volume":"19","author":"Pardanani","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.exphem.2010.05.004_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.iac.2006.05.003","article-title":"KIT mutations in mastocytosis and their potential as therapeutic targets","volume":"26","author":"Gotlib","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.exphem.2010.05.004_bib10","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2010.05.004_bib11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of\u00a0clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2010.05.004_bib12","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2010.05.004_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2141.2001.02783.x","article-title":"Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis","volume":"113","author":"Fritsche-Polanz","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2010.05.004_bib14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000048179","article-title":"Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts","volume":"127","author":"Feger","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.exphem.2010.05.004_bib15","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.004_bib16","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2010.05.004_bib17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0301-472X(98)00075-7","article-title":"Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit","volume":"27","author":"London","year":"1999","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2010.05.004_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/104063870401600201","article-title":"Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis","volume":"16","author":"Jones","year":"2004","journal-title":"J Vet Diagn Invest"},{"key":"10.1016\/j.exphem.2010.05.004_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1354\/vp.39-5-529","article-title":"Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs","volume":"39","author":"Zemke","year":"2002","journal-title":"Vet Pathol"},{"key":"10.1016\/j.exphem.2010.05.004_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/104063870501700416","article-title":"A study of mutations in the c-kit gene of 32 dogs with mastocytoma","volume":"17","author":"Riva","year":"2005","journal-title":"J Vet Diagn Invest"},{"key":"10.1016\/j.exphem.2010.05.004_bib21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood.V110.11.1541.1541","article-title":"Delineation of a KIT-independent oncogenic pathway in neoplastic mast cells that involves Lyn and Btk and can be disrupted by the KIT\/Lyn\/Btk-targeting drug dasatinib","volume":"110","author":"Gleixner","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.004_bib22","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2010.05.004_bib23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated forms of c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2010.05.004_bib24","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.004_bib25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.004_bib26","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.004_bib27","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"The tyrosine kinase-targeting drug PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of kit: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.004_bib28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.004_bib29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2010.05.004_bib30","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","article-title":"Dasatinib therapy for systemic mastocytosis: four cases","volume":"80","author":"Purtill","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2010.05.004_bib31","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2010.05.004_bib32","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1182\/blood.V108.11.3609.3609","article-title":"Phase II trial of the tyrosine kinase inhibitor PKC412 in advanced systemic mastocytosis: preliminary results","volume":"108","author":"Gotlib","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.004_bib33","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2010.05.004_bib34","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.004_bib35","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.004_bib36","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood-2006-03-013250","article-title":"INNO-406, a novel BCR-ABL\/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity","volume":"109","author":"Yokota","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2010.05.004_bib37","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1349-7006.2007.00516.x","article-title":"Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406","volume":"98","author":"Pan","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.exphem.2010.05.004_bib38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","article-title":"Establishment of an immature mast cell line from a patient with mast cell leukemia","volume":"12","author":"Butterfield","year":"1988","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.05.004_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/ajrcmb\/3.5.413","article-title":"Establishment of two dog mastocytoma cell lines in continuous culture","volume":"3","author":"DeVinney","year":"1990","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.exphem.2010.05.004_bib40","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.vetimm.2006.11.009","article-title":"Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells","volume":"115","author":"Rebuzzi","year":"2007","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.exphem.2010.05.004_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.10072","article-title":"Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA)","volume":"58","author":"Escribano","year":"2004","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.exphem.2010.05.004_bib42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","article-title":"Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings","volume":"25","author":"Horny","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2010.05.004_bib43","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.3324\/haematol.11996","article-title":"Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens","volume":"92","author":"Krauth","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2010.05.004_bib44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-6-85","article-title":"Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors","volume":"6","author":"Webster","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.exphem.2010.05.004_bib45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1439-0264.2002.00398.x","article-title":"Morphological and biochemical aspects of apoptosis, oncosis and necrosis","volume":"31","author":"Van Cruchten","year":"2002","journal-title":"Anat Histol Embryol"},{"key":"10.1016\/j.exphem.2010.05.004_bib46","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.exphem.2008.06.002","article-title":"Targeting of heat-shock protein 32\/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis","volume":"36","author":"Hadzijusufovic","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2010.05.004_bib47","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.exphem.2007.06.005","article-title":"Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells","volume":"35","author":"Gleixner","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2010.05.004_bib48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/00313020220147122","article-title":"C-kit mutations in gastrointestinal stromal tumours","volume":"34","author":"Morey","year":"2002","journal-title":"Pathology"},{"key":"10.1016\/j.exphem.2010.05.004_bib49","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0016-5085(98)70079-4","article-title":"A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors","volume":"115","author":"Nakahara","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.exphem.2010.05.004_bib50","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1523-1747.1998.00414.x","article-title":"Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior","volume":"111","author":"B\u00fcttner","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.exphem.2010.05.004_bib51","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1541-7786.MCR-09-0138","article-title":"The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment","volume":"7","author":"Bougherara","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.exphem.2010.05.004_bib52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.vetimm.2008.06.014","article-title":"Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells","volume":"126","author":"Ohmori","year":"2008","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.exphem.2010.05.004_bib53","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1939-1676.2008.00132.x","article-title":"Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs","volume":"22","author":"Isotani","year":"2008","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.exphem.2010.05.004_bib54","first-page":"301","article-title":"Innovation of clinical trials for anti-cancer drugs in Japan\u2014proposals from academia with special reference to the development of novel Bcr-Abl\/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia","volume":"34","author":"Maekawa","year":"2007","journal-title":"Gan To Kagaku Ryoho"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X10002006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X10002006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:28:15Z","timestamp":1759566495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X10002006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0301472X10002006"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2010.05.004","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KIT polymorphisms and mutations determine responses of neoplastic mast\u00a0cells to bafetinib (INNO-406)","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2010.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}